Skip to main content

SARS (Severe Acute Respiratory Syndrome) clinical trials at UC Health

2 in progress, 1 open to eligible people

Showing trials for
  • Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

    open to eligible people ages 18-80

    This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).

    at UCLA

  • Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19

    Sorry, not yet accepting patients

    COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure. We explore a treatment administered in a randomized clinical trial that could prevent ICU admission and reduce mortality. The overall hypothesis to be evaluated is that HBO reduce mortality, increase hypoxia tolerance and prevent organ failure in patients with COVID19 pneumonitis by attenuating the inflammatory response.

    at UCSD

Last updated: